DAY 3 Irish Biotech leads the way
Heart Metabolics completes $20M Series A funding to bring drugs on the market for Hypertrophic
cardiomyopathy (HCM) and other cardio-metabolic diseases. Read more here
DAY 3 Irish Biotech leads the way
Heart Metabolics completes $20M Series A funding to bring drugs on the market for Hypertrophic
cardiomyopathy (HCM) and other cardio-metabolic diseases. Read more here
Year of Positive Ireland 